Everything below concerns GIP receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
=== Design === Some teams are developing interoperable solutions, but this is not common. Governments express concerns over data sovereignty. WHO established a "working group focused on establishing standards for a common architecture for a digital smart vaccination certificate to support vaccine(s) against COVID-19 and other immunizations". The COVID-19 Credentials Initiative hosted by Linux Foundation Public Health (LFPH) is a global initiative working to develop and deploy privacy-preserving, tamper-evident and verifiable credential certification projects based on the open standard Verifiable Credentials (VCs).
== History == According to Junman Kang's King Gojong goes to Starbucks (한국어: 고종 스타벅스에 가다), Kang states that King Gojong was the first person to taste coffee in Korea. Antoinette Sontag, the sister-in-law of a Russian ambassador, treated the king to a cup of coffee in 1896. Koreans were curious about foreign cultures and the new beverage. Because it came from the West and resembled Asian herbal medicine that only the rich could afford, it was consumed as a symbol of westernization and modernization. In the early days, people called coffee shop or café "dabang". The very first dabang in Korea was built by Sontag as named Sontag Hotel at Junggu Jeongdong in Seoul in 1902. The modern type of dabangs dates from 1927 in Myeongdong and were spread to Jongno and Chungmuro. At first dabangs were open to the royal family and people in high positions and later were used as politicians' hall, artists' headquarters, and businessmen's meeting place. Koreans were fascinated by dabang because they enjoyed the practice of drinking coffee in dabang atmosphere; it was a great pleasure to experience using forks to have cake and drinking coffee in a teacup instead of using chopsticks and drinking Korean traditional soup out of a bowl. In mid-1900, dabangs continued to exist as a meeting place rather than as a place where people could drink coffee; however, it was not the time for ordinary citizens to consume coffee yet due to the high price.
This list contains a list of EC numbers for the second group, EC 2, transferases, placed in numerical order as determined by the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology. All official information is tabulated at the website of the committee. The database is developed and maintained by Andrew McDonald.
She befriends investor Jesse Bloom and secures him as a client by helping him seize control of healthcare startup Rican, undercutting Felim and contributing to Eric’s removal from the trading floor. Harper begins a relationship with new MD Daniel Van Deventer (DVD) and travels to Berlin to confront her estranged brother, who rebuffs her. When Pierpoint plans to fold London into New York, Harper engineers a survival bid with Eric to preserve a London office, getting DVD fired. After Jesse manipulates her into committing insider trading, Eric shields her by exposing her forged transcripts instead, getting her fired. In series 3, six weeks prior to the main events, Harper accompanies Yasmin on a cruise in Mallorca and helps cover up Charles Hanani’s drowning. In the present, Harper works at ethical fund FutureDawn, where she earns Petra Koenig’s trust during the tumultuous Lumi IPO by helping hedge her exposure; the two co-found their own firm, LeviathanAlpha, with backing from Otto Mostyn. Harper enlists Pierpoint as their broker to humiliate Eric and illegally plans a short of Pierpoint’s ESG-backed debt, using an unwitting Yasmin to obtain information. The betrayal damages their friendship. Harper ultimately abandons the short but partners with Otto months later to launch a new hedge fund focused on shorting corrupt firms they can control. She and Yasmin also reconcile. In series 4, Harper runs a short-only fund within Otto's asset management firm but grows frustrated with his tight oversight, later learning it is tied to his political interests.
=== As an antioxidant and short-wavelength light filter === Of the three macular carotenoids (lutein, zeaxanthin and meso-zeaxanthin), meso-zeaxanthin is the most powerful antioxidant, but a combination of the macular carotenoids has been shown to exhibit the greatest antioxidant potential when compared to the individual carotenoids at the same total concentration. This may explain why the human macula uniquely contains these three carotenoids out of about 700 carotenoids present in nature. Also, it has been shown that the combination of the carotenoids results in optimal light filtration (i.e., filtration of short-wavelength blue light) at the macula. This is important because short-wavelength light incident at the macula causes chromatic aberration and light scattering, phenomena that adversely affect visual function and result in poor contrast sensitivity.
Sources: en.wikipedia.org
== Epidemiology == Hypothyroidism is four times more common in women than men. The incidence of myxedema coma has been reported to be 0.22 per 1,000,000 per year but the data is limited and especially lacking in countries outside the western world and countries along the equator. Myxedema coma is most common in people 60 years old and older and is most common in the winter months when hypothermia is more common.
He added that Afghanistan had taken serious measures to ensure its territory was not used against Pakistan and said its military actions were defensive. Pakistan's Defence Minister, Khawaja Asif, implicitly confirmed that indirect talks with the Afghan Taliban were taking place through third-party mediators, although he described the process as unstructured and informal. He added that if the efforts failed to secure peace, Pakistan could return to its previous approach and escalate military operations in parts of Afghanistan. Pakistani military claimed to have killed 10 TTP militants in an operation in Khyber District and three more in Bannu. On 31 March, Taliban and Pakistani forces clashed in Dangam District of Kunar Province. On 1 April, 4 police personnel and 5 civilians were injured in an improvised explosive device (IED) blast carried out by Pakistani Taliban in Pakistan's Lakki Marwat district. On 2 April, Pakistani officials said that they foiled an infiltration attempt along the Afghanistan–Pakistan border, killing eight militants and seizing a large quantity of weapons and ammunition. That same day, Taliban and Pakistani officials confirmed that they were holding preliminary talks mediated by China in Ürümqi. Pakistani officials described the talks as working-level and said that they had sent their mid-level delegation to take part in the talks.
=== Sexual stimulation and arousal === The clitoris has an abundance of nerve endings, and is the human female's most erogenous part of the body. When sexually stimulated, it may incite sexual arousal, which may result from mental stimulation (sexual fantasy), activity with a sexual partner, or masturbation, and can lead to orgasm. The most effective sexual stimulation of this organ is usually manually or orally, which is often referred to as direct clitoral stimulation; in cases involving sexual penetration, these activities may also be referred to as additional or assisted clitoral stimulation. Direct stimulation involves physical stimulation to the external anatomy of the clitoris – glans, hood, and shaft. Stimulation of the labia minora, due to it being connected with the glans and hood, may have the same effect as direct clitoral stimulation. Though these areas may also receive indirect physical stimulation during sexual activity, such as when in friction with the labia majora, indirect clitoral stimulation is more commonly attributed to penile-vaginal penetration. Penile-anal penetration may also indirectly stimulate the clitoris by the shared sensory nerves (especially the pudendal nerve, which gives off the inferior anal nerves and divides into two terminal branches: the perineal nerve and the dorsal nerve of the clitoris).
=== Shared care === Shared decision making is an approach whereby patients and clinicians freely share important evidence when tasked with decision making and where patients are guided to consider the best available options to make an informed decision. The principles are well documented, but there is a gap in that it's hard to apply them in routine clinical practice. The steps have been simplified into five steps. The first step is seeking patient participation in that the health practitioner is tasked with communicating existing choices and therefore inviting them to the decision-making process. The next step involves assisting the patient to explore and compare the treatment options by a critical analysis of the risks and benefits. The third step involves the assessment of the patient's values and what they prefer taking to account what is of paramount urgency to the patient. Step 4 involves decision making where the patient and the practitioner make a conclusive decision on the best option and arrange for subsequent follow up meetings. Finally, the fifth step involves the analysis of the patient's decision'. Five steps for you and your patients to work together to make the best possible health care decisions. The step involves monitoring of the degree of implementation, overcoming of barriers of decision implantation consequently the decisions need to be revisited and optimized thus ensuring the decision has a positive impact on health outcomes. Its success relies on the ability of the health practitioner to create a good interpersonal relationship with the patient.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.